ABSK021
Phase 2Small molecule
ABSK021 is one of 44 small molecule programs targeting Chronic Graft Versus Host Disease. It is currently in Phase 2.
1
Indications
4
Total Trials
2
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Chronic Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Neoral
NovartisApproved
Erivedge
RocheApproved
Olumiant
Eli LillyApproved
Decadron
AAspen Global Incorporated
Approved
Kyprolis
VVirionyx Corporation Limited
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Pulmicort
SSalix
Approved
Qvar
SSchering-Plough
Approved
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clinical Trial1 trial
Advanced Solid Tumor1 trial
Chronic Graft Versus Host Disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABSK021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAbbisko Therapeutics Co, Ltd